Nalpain (Nalbuphine Hydrochloride)

Nalbuphine works by activating kappa opioid receptors, which produce analgesia and sedation, while simultaneously blocking mu opioid receptors, reducing typical opioid‑related side effects such as respiratory depression. This dual action results in effective pain control with a distinct safety profile.

The appropriate dose of Nalpain is determined by the prescribing clinician based on the patient’s pain severity, clinical condition, and response to therapy. Dosage may be adjusted for factors such as age, weight, and hepatic function, and should follow local prescribing guidelines.

The safety of nalbuphine in pregnancy and lactation has not been fully established. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To order Nalpain, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details and any required import documentation.

Compared with pure mu‑agonist opioids, nalbuphine’s mixed kappa‑agonist/mu‑antagonist profile offers effective analgesia with a lower risk of respiratory depression and dependence. This makes it a useful alternative when clinicians seek strong pain relief while minimizing certain opioid‑related adverse effects.

Nalpain should be stored at ambient temperature, below 25 °C, in its original container. Protect the product from moisture, direct sunlight, and extreme temperatures to maintain its stability and sterility.

Nalpain is supplied as a sterile injectable solution and can be given intramuscularly, intravenously, or subcutaneously. Administration should be performed by qualified healthcare personnel following aseptic technique and appropriate dosing guidelines.

The most serious risks include respiratory depression, severe hypotension, allergic reactions such as anaphylaxis, and rare seizures. Patients should be closely monitored for these events, especially when receiving high doses or when combined with other central nervous system depressants.

Nalpain is contraindicated in patients with known hypersensitivity to nalbuphine or any formulation components, those with severe respiratory insufficiency, and individuals who have taken monoamine oxidase inhibitors within the past 14 days. Caution is also advised in patients with significant hepatic impairment.